FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a monoclonal antibody that specifically binds the KIR3DL2 polypeptide, as well as a pharmaceutical composition for treating cancer or an inflammatory or autoimmune disorder comprising it. Host cell modified with a heterologous DNA encoding the above antibody is also disclosed. Invention also relates to a method of treating or preventing a disease, wherein the elimination of KIR3DL2 expressing cells, a method for identifying a KIR3DL2 expressing cell in a subject’s body, a method for identifying a KIR3DL2 expressing of T-cell lymphoma in a subject, as well as to a method for selecting subjects with T-cell lymphoma responding to treatment with an antibody that specifically binds the KIR3DL2 polypeptide, using the above antibody.
EFFECT: invention makes it possible to effectively treat cancer or an inflammatory or autoimmune disorder in which the elimination of KIR3DL2 expressing cells would be beneficial.
29 cl, 20 dwg, 7 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | 2018 |
|
RU2781116C1 |
| MICA BINDING AGENTS | 2013 |
|
RU2656183C2 |
| DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
| PEPTIDE OR PEPTIDE COMPLEX BINDING TO alpha2- INTEGRIN, METHODS FOR PRODUCTION AND USE THEREOF | 2011 |
|
RU2588668C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| ANTIBODIES AND CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO CD19 | 2015 |
|
RU2741105C2 |
| MODIFIED EPITOPES FOR AMPLIFYING RESPONSES OF CD4+ T-CELLS | 2013 |
|
RU2724994C2 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS FOR USE THEREOF | 2013 |
|
RU2681994C2 |
